lawsuits against semaglutide Ozempic Vision Lawsuit Lawsuits claiming Ozempic, other GLP-1s

Procedures All participants initially received open-label once-weekly subcutaneous semaglutide, 0.25 mg, increased every 4 weeks to the maintenance dose of 2.4 mg once weekly by week 16, and continued to week 20 (run-in period

"We also expect there to be some benefits in terms of cardiovascular benefits, kidney benefits, and liver benefits because it has demonstrated reduced liver fat in earlier studies,' Jonsson said

Blood pressure should be monitored

This was recently supported by evidence that AGRP neurons (which when activated potently drive feeding behaviour) project to paraventricular hypothalamic nucleus oxytocin neurons (Figure 2) (Atasoy et al., 2012)